ADK

ADK Full Name

adenosine kinase

ADK Introduction

Adenosine kinase (ADK) is a highly conserved phosphotransferase and the paramount metabolic enzyme responsible for regulating the cellular and extracellular levels of adenosine. Structurally, ADK relies on ATP and magnesium to catalyze the phosphorylation of adenosine into adenosine monophosphate (AMP). Because ADK possesses an exceptionally high affinity for adenosine (low Km), it acts as the primary metabolic "sink" or clearance mechanism for this purine under baseline physiological conditions. Adenosine itself is a potent endogenous signaling molecule and a universal distress signal that operates through specific G-protein-coupled receptors (A1, A2A, A2B, and A3). By suppressing cellular excitability, reducing tissue inflammation, and regulating energy homeostasis, adenosine acts as an intrinsic neuroprotective and tissue-protective agent. Consequently, minor fluctuations in ADK enzyme activity dictate the ambient "adenosinergic tone," making ADK the master regulator of purinergic signaling. Furthermore, by clearing intracellular adenosine, ADK critically drives the transmethylation cycle, maintaining the S-adenosylmethionine (SAM) to S-adenosylhomocysteine (SAH) ratio essential for global DNA and histone methylation.

Figure 1. Adenosine metabolic pathways and major enzymes involved. (Source: Boison D, et al. 2010)

Clinically, the pathological dysregulation of ADK is a fundamental driver in severe neurological, metabolic, and oncological disorders. In the central nervous system, ADK is predominantly expressed in astrocytes. During brain injury, trauma, or severe neuroinflammation, reactive astrogliosis leads to a massive, pathological overexpression of ADK. This upregulation rapidly depletes the brain's neuroprotective adenosine pool, thereby removing the endogenous "brakes" on neuronal firing. This deficiency in adenosinergic inhibition triggers severe neuronal hyperexcitability, neurotoxicity, and the robust development of epilepsy (epileptogenesis). Conversely, pharmacological inhibition or genetic downregulation of ADK raises ambient adenosine levels, demonstrating profound and long-lasting anticonvulsant properties.

Beyond neurology, aberrant ADK activity is deeply implicated in metabolic syndromes and organ fibrosis. In the liver, altered ADK expression disrupts the cellular methylation potential, driving hepatic steatosis and accelerating the progression of liver fibrosis. In the field of oncology, ADK is increasingly recognized for shaping the tumor microenvironment; tumor cells manipulate purinergic signaling and ADK levels to evade immune surveillance and fuel rapid proliferation. Because it acts at the critical intersection of energy metabolism, epigenetic regulation, and immune modulation, ADK is actively being pursued as a highly promising therapeutic target for treating intractable epilepsy, metabolic diseases, and cancer.

Alternate Names for ADK

ADK; adenosine kinase; adenosine 5 phosphotransferase; AK; adenosine 5-phosphotransferase;

• 1. Boison D, et al. Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death. Open Drug Discov J. 2010 Jan 1;2(3):108-118.
  2. Boison D, et al. Adenosine kinase: A key regulator of purinergic physiology. Biochem Pharmacol. 2021 May;187:114321.